Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore

Journal of Rheumatology

Volumn 26, Issue 1, 1999, Pages 97-102

  Thumboo, Julian ^a,b   Fong, Kok Yong ^a   Ng, Tze Pin ^a   Leong, Keng Hong ^a   Feng, Pao Hsi ^a   Thio, Szu Tien ^a   Boey, Mee Leng ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Asia; Bilag disease activity index; Quality of life; SF 36; SLICC ACR damage index; Systemic lupus erythematosus

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; REPRODUCIBILITY; SINGAPORE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VALIDATION PROCESS;

COHORT STUDIES; CROSS-OVER STUDIES; DEMOGRAPHY; EVALUATION STUDIES; HEALTH CARE SURVEYS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SINGAPORE;

EID: 0032891503     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hochberg MC. Systemic lupus erythematosus. Rheum Dis Clin North Am 1990;16:617-39.
2. Isenberg DA, Bacon P, Bombardier C, et al. Criteria for assessing disease activity in systemic lupus erythematosus. J Rheumatol 1989;16:1395-6.
3. Gladman D, Urowitz M, Fortin P, et al. Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. J Rheumatol 1996;23:1953-5.
4. Stoll T, Gordon C, Seifert B, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997;24:1608-14.
5. Gladman DD, Urowitz MB, Cough J, MacKinnon A. Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol 1997;24:2145-8.
6. Hay EM, Bacon PA, Gordon C, et al. The BILAG Index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
7. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the SLICC/ACR damage index for SLE. Arthritis Rheum 1996;39:363-9.
8. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982;25:1271-7.
9. Ware JE, Sherbourne CD. The MOS 36-Item Short Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1991;30:473-83.
10. McHorney C, Ware JE, Raczek A. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31:247-63.
11. McHorney C, Ware JE, Lu J, Sherbourne C. The MOS 36-Item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
12. Ware JE. SF-36 Health Survey: Manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
13. Gladman DD, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
14. Gladman DD, Urowitz M, Goldsmith C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
15. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are useful predictors of severe outcome in patients with SLE. Br J Rheumatol 1996;35: 248-54.
16. Gladman DD, Goldsmith C, Urowitz M, et al. The SLICC/ACR Damage Index for SLE international comparison [abstract]. Arthritis Rheum 1997;38 Suppl 1:S174.
17. Ehrenstein MR, Longhurst CM, Latchman DS, Isenberg DA. Serological and genetic characterisation of a human monoclonal immunoglobulin G anti-DNA idiotype. J Clin Invest 1994;93: 1787-97.
18. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996;55:756-60.
19. Stoll T, Stucki G, Malik I, Pyke S, Isenberg DA. Association of the Systemic Lupus Erythematosus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 1997;24:309-13.
20. Stoll T, Stucki G, Gordon C, Isenberg DA. A damage index for lupus patients - where are we now? Lupus 1997;6:219-22.
21. Bland JG, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1: 307-10.
22. Gladman DD, Urowitz MB, Ong A, Gough J, MacKinnnon A. Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol 1996;14:305-8.
23. Hanly JG. Disease activity, cumulative damage and quality of life in systemic lupus erythematosus: results of a cross sectional study. Lupus 1997;6:243-7.
24. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. Oxford: Oxford University Press; 1989:8.
25. Gordon C, Exley AR, Clay C, Stoll T, Isenberg DA, Bacon PA. Changes in SF-36 scores in SLE patients with change in disease activity measured by the BILAG index [abstract]. Arthritis Rheum 1997;40 Suppl:S112.
26. Karlson EW, Daltroy LH, Lew RA, et al. The relationship of socioeconomic status, race and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:47-56.
27. Petri M, Steckroth D. Fibromyalgia, not active SLE, explains fatigue, HAQ scores, disability and depression scores [abstract]. Arthritis Rheum 1996;39 Suppl 1:S68.
28. Ruta DA, Abdalla MI, Garratt AM, Coutts A, Russell IT. SF-36 health survey questionnaire: I. reliability in two patient based studies. Quality in Health Care 1994:3:180-5.
29. Ware JE, Kosinski M. SF-36 Health Survey (version 2.0) technical note. Boston: Health Assessment Lab; 1996 (updated 1997).
30. Dupont WD, Plummer WD. Power and sample size calculations. A review and computer programme. Controlled Clin Trials 1990;11:116-28.
31. Thumboo J, Fong KY, Ng TP, Leong KH, Feng PH, Boey ML. Initial construct cross-cultural validation of the Short Form 36 for quality of life assessment of systemic lupus erythematosus patients in Singapore. Ann Acad Med Singapore 1997;26:282-4.